NCT03394118 is a Phase 2 clinical trial of Osimertinib in NSCLC, sponsored by Asan Medical Center.

Who is sponsoring NCT03394118?

NCT03394118 is sponsored by Asan Medical Center.

What drugs are being tested in NCT03394118?

Interventions in NCT03394118: Osimertinib.

Is NCT03394118 still recruiting?

NCT03394118 is currently completed. Last updated 27 April 2021.

Last reviewed 2021-04-27 · How we verify

NCT03394118

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

Completed Phase 2 Last updated 27 April 2021

What this trial tests

Phase 2 trial testing Osimertinib in NSCLC in 63 participants. Completed in 8 April 2021.

Timeline

11 August 2017

Primary endpoint
11 March 2021

8 April 2021

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	11 August 2017
Primary completion	11 March 2021
Estimated completion	8 April 2021
Sites	1 location across South Korea

Drugs / interventions tested

Osimertinib (osimertinib) — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →

Sponsor

Asan Medical Center

Who can join

20 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this trial, anti-tumor efficacy of TAGRISSO in NSCLC patients in whom T790 mutations are detected by liquid biopsy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid Biopsies: Emerging role and clinical applications in solid tumours.
Sisodiya S, Kasherwal V, Khan A, Roy B, et al · · 2023 · cited 21× · PMID 37327582 · DOI 10.1016/j.tranon.2023.101716
Circulating tumor DNA: Where are we now? A mini review of the literature.
Galarza Fortuna GM, Dvir K. · · 2020 · cited 11× · PMID 33033694 · DOI 10.5306/wjco.v11.i9.723
Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.
Ranganathan K, Kurian NS, Goswami HM, Rishi KD, et al · · 2024 · cited 5× · PMID 40027943 · DOI 10.1016/j.jlb.2024.100150

Verify or expand the search:

Other trials of Osimertinib

Trials testing the same drug.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT07376382 — A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCL · Phase 3 · not yet recruiting
NCT07323641 — Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07329322 — Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Tre · Phase 2 · not yet recruiting
NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03394118 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 27 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03394118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing